NCT02828592View on ClinicalTrials.gov

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 9, 2016

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Severe Aplastic Anemia
Interventions
DRUG

Fludarabine

30 mg/m2 IV QD x 5 days (Days -6 to -2)

DRUG

Cyclophosphamide

14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)

RADIATION

Total Body Irradiation

300 cGy x1 dose (Day -1)

DRUG

Rabbit ATG

1.5 mg/kg/day x 3 days (Days -3 to -1)

DRUG

Cyclophosphamide

Post-transplant: 50 mg/kg IV QD (Day +3 to +4)

Trial Locations (2)

30342

RECRUITING

Blood and Marrow Transplant Group of Georgia, Atlanta

RECRUITING

Northside Hospital, Atlanta

All Listed Sponsors
lead

Northside Hospital, Inc.

OTHER

NCT02828592 - Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter